OXFORD, England, March 2, 2011 /PRNewswire/ -- Syntaxin, a biotechnology
company developing novel biopharmaceuticals to control cell secretion, today
announces its partner Allergan, Inc has initiated two Phase II trials to
evaluate the safety and efficacy of its re-targeted endopeptidase drug
ca